MAP Pharmaceuticals Inc. (MAPP) announced after the bell Wednesday that its New Drug Application resubmission for LEVADEX orally inhaled migraine drug, for the potential acute treatment of migraine in adults, has been accepted for filing by the FDA.
MAP Pharmaceuticals has gapped open sharply higher Friday morning and is now up 2.17 at $14.99 on above average volume. The stock has jumped to over a 2-week high and has re-crossed its 200-day moving average.
For comments and feedback: editorial@rttnews.com